GlaxoSmithKline received some good news from the U.S. Food and Drug Administration on Tuesday concerning its proposed cancer drug Oral Hycamtin. The FDA granted it priority review.

The accelerated decision making process means the drug could receive approval within six months rather than 10 months, the Associated Press reported Tuesday.

Oral Hycamtin targets an aggressive form of lung cancer that affects some 15 percent of those patients with the disease. The chemotherapy is delivered orally and can be taken at home.